ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio is a biotechnology company that operates in the United States and Europe, with a majority of its revenue coming from the United States. The positive outlook is based on the company's strong clinical trial data shown at ASCO 2026 that supports a broader view of ANKTIVA as an IL-15 receptor agonist platform with potential relevance across various settings where checkpoint resistance, lymphopenia and insufficient immune memory remain key therapeutic barriers. Additionally, upcoming catalysts such as the January 2027 PDUFA for ANKTIVA in BCG-unresponsive papillary NMIBC and Phase 3 data in BCG-naïve CIS NMIBC provide potential for further growth. However, the strength of the NSCLC data may raise questions about regulatory approval and competition in the market.

ImmunityBio is struggling to gain approval from the FDA for their immunotherapies in papillary-only disease, due to the agency's preference for randomized studies to isolate the treatment effect of their product from surgery alone. This has resulted in major delays and uncertainty for the company's pipeline, with even FDA-approved immunotherapy companies like JNJ facing challenges in this space. Additionally, the company's reliance on the US market for the majority of its revenue exposes it to potential regulatory changes and market saturation in the highly competitive biotech industry. As a financial analyst, it is difficult to see how ImmunityBio's stock will outperform given these fundamental challenges.